NDAORALTABLET
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
3
Mechanism of Action
Endothelin Receptor Antagonists
Pharmacologic Class:
Endothelin Receptor Antagonist
Clinical Trials (3)
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
Started Jan 2020
0HypertensionRenal Insufficiency, Chronic
A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects
Started Jul 2018
20 enrolled
Healthy Subjects
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
Started Jun 2018
730 enrolled
Resistant Hypertension
Loss of Exclusivity
LOE Date
Jul 26, 2038
150 months away
Patent Expiry
Jul 26, 2038
Exclusivity Expiry
Mar 22, 2029